Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Biotransformation and bioactivation reactions of alicyclic amines in drug molecules.

Bolleddula J, DeMent K, Driscoll JP, Worboys P, Brassil PJ, Bourdet DL.

Drug Metab Rev. 2014 Aug;46(3):379-419. doi: 10.3109/03602532.2014.924962. Epub 2014 Jun 9. Review.

PMID:
24909234
2.

On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics.

Kalgutkar AS, Dalvie DK, O'Donnell JP, Taylor TJ, Sahakian DC.

Curr Drug Metab. 2002 Aug;3(4):379-424. Review.

PMID:
12093357
3.

Bioactivation of drugs: risk and drug design.

Walsh JS, Miwa GT.

Annu Rev Pharmacol Toxicol. 2011;51:145-67. doi: 10.1146/annurev-pharmtox-010510-100514. Review.

PMID:
21210745
4.
5.

Non-cytochrome P450-mediated bioactivation and its toxicological relevance.

Gan J, Ma S, Zhang D.

Drug Metab Rev. 2016 Nov;48(4):473-501. Epub 2016 Sep 20. Review.

PMID:
27533622
6.

A comprehensive listing of bioactivation pathways of organic functional groups.

Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP.

Curr Drug Metab. 2005 Jun;6(3):161-225. Review.

PMID:
15975040
7.

Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes.

Castagnoli N Jr, Rimoldi JM, Bloomquist J, Castagnoli KP.

Chem Res Toxicol. 1997 Sep;10(9):924-40. Review.

PMID:
9305573
8.

Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Shu YZ, Johnson BM, Yang TJ.

AAPS J. 2008;10(1):178-92. doi: 10.1208/s12248-008-9016-9. Epub 2008 Mar 13. Review.

10.

In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery.

Prakash C, Sharma R, Gleave M, Nedderman A.

Curr Drug Metab. 2008 Nov;9(9):952-64.

PMID:
18991592
11.

Minimising the potential for metabolic activation in drug discovery.

Kalgutkar AS, Soglia JR.

Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):91-142. Review.

PMID:
16922655
12.

Characterization of human cytochrome P450s involved in the bioactivation of clozapine.

Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN.

Drug Metab Dispos. 2013 Mar;41(3):651-8. doi: 10.1124/dmd.112.050484. Epub 2013 Jan 7. Erratum in: Drug Metab Dispos. 2013 Apr;41(4):923.

13.

Addressing metabolic activation as an integral component of drug design.

Doss GA, Baillie TA.

Drug Metab Rev. 2006;38(4):641-9. Review.

PMID:
17145693
14.

Cytochrome P450s: mechanisms and biological implications in drug metabolism and its interaction with oxidative stress.

Bhattacharyya S, Sinha K, Sil PC.

Curr Drug Metab. 2014;15(7):719-42. Review.

PMID:
25429675
15.
16.

Studies on the oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridines.

Castagnoli N Jr, Castagnoli K, Magnin G, Kuttab S, Shang J.

Drug Metab Rev. 2002 Aug;34(3):533-47. Review.

PMID:
12214665
17.

Carbon-carbon bond cleavage and formation reactions in drug metabolism and the role of metabolic enzymes.

Bolleddula J, Chowdhury SK.

Drug Metab Rev. 2015;47(4):534-57. doi: 10.3109/03602532.2015.1086781. Epub 2015 Sep 22. Review.

PMID:
26390887
18.

Quantitative assessment of the metabolic activation of alicyclic amines via aldehyde.

Miura M, Hori W, Kasahara Y, Nakagawa I.

J Pharmacol Toxicol Methods. 2010 Jan-Feb;61(1):44-51. doi: 10.1016/j.vascn.2009.10.005. Epub 2009 Nov 10.

PMID:
19903534
19.

The role of biotransformation and bioactivation in toxicity.

Dekant W.

EXS. 2009;99:57-86. Review.

PMID:
19157058
20.

The metabolism of tertiary amines.

Rose J, Castagnoli N Jr.

Med Res Rev. 1983 Jan-Mar;3(1):73-88. Review.

PMID:
6341732

Supplemental Content

Support Center